ການຄົ້ນຄວ້າ New Cleveland Clinic ສະແດງໃຫ້ເຫັນເປັນຄັ້ງທໍາອິດວ່າ ibrutinib (ibrutinib) ທີ່ໄດ້ຮັບການອະນຸມັດຈາກ FDA ສໍາລັບ lymphoma ແລະ leukemia ຍັງສາມາດຊ່ວຍປິ່ນປົວເນື້ອງອກໃນສະຫມອງທີ່ພົບເລື້ອຍທີ່ສຸດແລະຕາຍ, ແລະມື້ຫນຶ່ງອາດຈະຖືກນໍາໃຊ້ໃນຄົນເຈັບທີ່ມີ glioblastoma ແລະປັບປຸງອັດຕາການຢູ່ລອດ.
ອີງຕາມບົດລາຍງານຂອງສະມາຄົມໂຣກ tumor ສະຫມອງຂອງອາເມລິກາ, ອັດຕາການຢູ່ລອດຂອງ glioblastoma ແມ່ນຕໍ່າຫຼາຍ, ແລະການຢູ່ລອດສະເລ່ຍຂອງຄົນເຈັບທີ່ໄດ້ຮັບການປິ່ນປົວມາດຕະຖານແມ່ນຫນ້ອຍກວ່າ 15 ເດືອນ. Glioblastoma ແມ່ນເນື້ອງອກໃນສະຫມອງຕົ້ນຕໍທີ່ຕາຍແລ້ວທີ່ສຸດແລະທົນທານຕໍ່ການປິ່ນປົວໃນປະຈຸບັນ. ມີຄວາມຈໍາເປັນອັນຮີບດ່ວນເພື່ອໃຫ້ຄົນເຈັບເຫຼົ່ານີ້ມີການປິ່ນປົວໃຫມ່ໄວເທົ່າທີ່ຈະໄວໄດ້.
In an earlier study, Bao and colleagues found that glioma stem cells contained high levels of a protein called BMX (bone marrow and X-linked non-receptor tyrosine kinase). BMX activates a protein called STAT3 (signal transduction and transcription activator 3), which is responsible for the invasive and tumorigenic properties of glioma stem cells. In this new study, the researchers found that ibrutinib works by inhibiting two proteins.
A research team led by Dr. Shideng Bao of the Cleveland Clinic Lerner Institute found that ibrutinib slowed the growth of brain ເນື້ອງອກ in a preclinical model and prolonged survival by more than 10 times that of existing standard chemotherapy drugs. Studies have found that ibrutinib works by inhibiting glioma stem cells, an aggressive brain cancer cell that tends to resist treatment and spread. In addition, combining ibrutinib with radiation therapy can prevent glioblastoma cells from developing drug resistance. Combination therapy is more effective than radiotherapy or ibrutinib alone in overcoming drug resistance and extending lifespan. Follow-up clinical trials are being carried out intensively, and we look forward to receiving FDA approval as soon as possible.
https://medicalxpress.com/news/2018-05-leukemia-lymphoma-drug-benefit-glioblastoma.html
